BEHAVIORAL EVALUATION OF IMIPRAMINE AND NIALAMIDE IN REGRESSED SCHIZOPHRENIC PATIENTS WITH DEPRESSIVE FEATURES
Abstract
Imipramine and nialamide were found to be comparable as measured by psychiatrist's clinical ratings of over-all improvement in patients with depressive symptoms. On measures of specffic behavioral factors on the MACC scale the two drug groups were differentiated by improved motility in patients on imipramine and by positive changes in affect in patients receiving nialamide during the first 6 weeks of drug administration.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
